Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00212615
Status:
COMPLETED
Last Update Posted:
2020-11-06
First Post:
2005-09-13
Brief Title:
XELOX III Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer
Sponsor:
Odense University Hospital
Organization:
Odense University Hospital
Study Overview
Official Title:
XELOX III Capecitabine Xeloda in Combination With Oxaliplatin Eloxatin as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer A Randomized Phase II Study
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
XELOX Capecitabine and Oxaliplatin is an effective and convenient regimen for patients with metastatic colorectal cancer Chronomodulated therapy may reduce toxicity Patients will be randomized to standard XELOX Capecitabine 1000 mgm² in the morning and 1000 mgm² in the evening days 1-14 and short term Oxaliplatin 130 mgm² day 1 in 30 minutes or chronomodulated XELOX Capecitabine 400 mgm² in the morning and 1600 mgm² in the evening days 1-14 and short term Oxaliplatin 130 mgm² day 1 in 30 minutes
Bloodsamples will be collected and frozen and later examined for potential predictive factors
Bloodsamples will be collected and frozen and later examined for potential predictive factors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| KFE 0317 | None | None | None |